Aggressive investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
any question ask them nfo@hemispherx.net
they are answering
$HEB Good morning faithful longs. Good on ya!
$HEB being set up in pre-market
for massive run
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10118040.htm
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10118040.htm
Hemispherx Biopharma (HEB) Ampligen Produces 100% Survival Rate in Ebola Virus Rodent Study
http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+(HEB)+Ampligen+Produces+100%25+Survival+Rate+in+Ebola+Virus+Rodent+Study/10215328.html
Hemispherx Biopharma (HEB) Ampligen Produces 100% Survival Rate in Ebola Virus Rodent Study
http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+(HEB)+Ampligen+Produces+100%25+Survival+Rate+in+Ebola+Virus+Rodent+Study/10215328.html
$HEB *Hemispherx Says US Army Scientists Report Ampligen 100% Survival Rate in Ebola Virus Rodent Study (Benzinga)
$HEB *Hemispherx Says US Army Scientists Report Ampligen 100% Survival Rate in Ebola Virus Rodent Study (Benzinga)
Keep an eye on HEB ...
Update on Ebola soon. Got money from uncle SAM
Keep an eye on HEB ...
Update on Ebola soon. Got money from uncle SAM
Zogenix, Inc. (ZGNX) New Formulation Receives FDA Approval
http://www.bidnessetc.com/33787-zogenix-inc-zgnx-new-formulation-receives-fda-approval/
Why the modern world is bad for your brain
http://www.theguardian.com/science/2015/jan/18/modern-world-bad-for-brain-daniel-j-levitin-organized-mind-information-overload?sf7120800=1
Nuvo Research® Reports Topline Results of Phase 2 Study of WF10â„¢ for the Treatment of Allergic Rhinitis
- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET -
MISSISSAUGA, ON, Jan. 30, 2015 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents. The study included three active arms (the Active Arms): a) WF10; b) WF10 with chlorate and sulphate removed; and c) WF10 with chlorite and sulphate removed. Each of the Active Arms was compared to a placebo arm in which patients received saline. Active or placebo treatments were administered by five intravenous infusions given once per day during the first five days of the study. The primary endpoint was change in Total Nasal Symptom Score (TNSS) from baseline to assessment after three weeks. TNSS is a validated scale to measure nasal symptoms associated with allergic rhinitis.
Topline Findings of the Study are:
The WF10 arm demonstrated a reduction in TNSS over the course of the observation period, similar to the reduction in TNSS demonstrated in the WF10 arm in the Company's previous 2010 Phase 2 proof-of-concept study described further below.
The placebo arm demonstrated a reduction in TNSS over the course of the observation period that was significantly greater than demonstrated in the placebo arm of the Company's 2010 Phase 2 proof-of-concept study.
Each of the Active Arms demonstrated a greater reduction in TNSS than placebo; however, (i) the difference between the WF10 arm and the placebo arm did not achieve statistical significance 3 weeks after commencement of the study which was the study's primary endpoint and (ii) the difference between the Active Arms and the placebo arm did not achieve statistical significance at measured time points over the course of the observation period.
Treatments administered in the Active Arms were well tolerated with favourable safety profiles.
The Company is conducting a detailed review of the data and expects to release further information and analysis of the data including information on secondary endpoints in the coming weeks.
"While the WF10 arm performed as expected, the placebo arm demonstrated a much greater than anticipated reduction in allergy symptom scores," said Dr. Henrich Guntermann, President, Europe & Immunology Group. "The cold and wet allergy season in Germany may have reduced symptoms for all patients in the study and possibly impacted the difference in symptoms between the WF10 arm and the placebo arm. We are conducting a more detailed analysis of the data which we will report when it becomes available."
About the WF10 Phase 2 Clinical Trial
184 patients were enrolled in and 179 patients completed the WF10 Phase 2 allergic rhinitis clinical trial that commenced in March 2014 at 15 sites in Germany. The 16-week trial was a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of a regimen of five infusions of either WF10 or its main constituents (sodium chlorite and sodium chlorate) relative to saline control in patients who suffer from refractory allergic rhinitis with positive skin test to at least one allergen. 46 patients were enrolled in each of 4 arms to receive WF10, WF10 with chlorate removed, WF10 with chlorite removed or placebo (saline). The trial measured total nasal symptom score (TNSS), total ocular symptom score (TOSS) and other secondary endpoints. The trial was designed to confirm the results of the Company's 2010 Phase 2 WF10 proof-of-concept clinical trial for the treatment of allergic rhinitis with WF10 which achieved statistical significance (P<0.001) for its primary endpoint (change in TNSS at week 3). It was also designed to provide information on which WF10 constituent elements are contributing to its therapeutic benefit.
About the 2010 WF10 Phase 2 Proof-of-Concept Study
In 2010, the Company conducted a Phase 2 proof-of-concept clinical trial to evaluate WF10 as a treatment for persistent allergic rhinitis. The trial was a 60-subject, randomized, double-blind, placebo-controlled, single-center trial to assess the efficacy and safety of a regimen of five WF10 infusions. The trial met its primary endpoint as measured by the change in Total Nasal Symptom Score (TNSS) from baseline to assessment after three weeks comparing the WF10 group with the placebo group. The trial also met its secondary endpoints as measured by the change in TNSS at six, nine and twelve weeks and in the Total Ocular Symptom Score (TOSS) from baseline to assessment after three, six, nine and twelve weeks. The TNSS and TOSS are validated scales to measure nasal and ocular symptoms associated with allergic rhinitis. The results were statistically significant for all primary and secondary endpoints with p-values less than 0.001 except for the change in TOSS after three weeks for which the p-value was less than 0.003. WF10 was very well tolerated and there were few reported adverse events.
About Allergic Rhinitis
Allergic rhinitis is a highly prevalent condition characterized by nasal symptoms (runny, blocked, or itchy nose; chronic sneezing) triggered by an inappropriate immune response to one or more allergens such as pollens, house dust mites and pet dander. Refractory allergic rhinitis patients usually show strong symptoms and do not respond adequately to common forms of treatment such as antihistamines or inhaled corticosteroids. It is estimated that there are 82 million allergy patients in the United States of which approximately 10 million suffer from allergic rhinitis that is refractory.
About WF10
WF10 is a solution containing stabilized chlorite ions that focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function. WF10 is an infusion therapy currently approved only in Thailand under the name IMMUNOKINE for the treatment of post-radiation-therapy syndromes and adjunctive therapy of diabetic foot ulcers.
Management to Host Conference Call/Webcast
Management will host a conference call to discuss the results from the WF10 Phase 2 trial today (January 30, 2015) at 8:30 a.m. ET. To participate in the conference call, please dial 1 (888) 231-8191 or (647) 427-7450, reference number 78033834. Please call in 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins.
A taped replay of the conference call will be available two hours after the live conference call and will be accessible until Friday, February 6, 2015 by calling 1 (855) 859-2056 or (416) 849-0833, reference number 78033834.
A live audio webcast of the conference call will be available through www.nuvoresearch.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.
About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Immunology Group and the Topical Products and Technology (TPT) Group. The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders. The TPT Group currently has four commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and two drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. For additional company information visit www.nuvoresearch.com.
swing GENE
Thought about get in yesterday. What a miss
http://www.reuters.com/article/2015/01/28/us-abiomed-forecast-idUSKBN0L02TY20150128
Pre market up by $16.00
What Investors Are Watching Ahead of Zogenix's FDA Approval Decision
http://www.benzinga.com/trading-ideas/long-ideas/15/01/5173335/what-investors-are-watching-ahead-of-zogenixs-fda-approval-de#ixzz3Q7lwGXjL
Zacks: Analysts Set $28.33 Target Price for Dynavax Technologies (NASDAQ:DVAX)
http://www.lulegacy.com/2015/01/27/zacks-analysts-set-28-33-target-price-for-dynavax-technologies-nasdaqdvax/
Way too low!!!!
Zacks: Analysts Set $28.33 Target Price for Dynavax Technologies (NASDAQ:DVAX)
http://www.lulegacy.com/2015/01/27/zacks-analysts-set-28-33-target-price-for-dynavax-technologies-nasdaqdvax/
Way too low!!!!
Someone mentioned MEIP on this board last week. Thanks for that.
I am in for long as prospect look good for future.
Essa Pharma Inc. (EPI)- Not bad First day trading so far
Low: $3.50 and High $4.00
http://web.tmxmoney.com/quote.php?qm_symbol=EPI
Talked to PR. NASDAQ listing on the way
Regards, Colorofmoney
Nuvo's WF10 and WF10 Valuation Using Cannacord Circassian discount model
TSX: NRI OTC: NRIFF
Most investors here have not yet understood the real significance of WF10 in the treatment of AR and other allergic illnesses.
No drug has yet been developed that can effectively treat poly synthesized patients for AR or the other immune diseases such as conjunctivitis and allergic asthma.
Each and every drug either developed ( like Mercks Grastek ) or in clinical trials (eg Circasia ) is based on only mono synthesized patients .
These must go thru initial allergic testing to identify the precipitate agent ... Ragweed , dust mites etc.
Yet , after administering their specific drug, levels of patient response while statistically significant is rather modest .
The reason for such a tepid patient response is that most of the allergic population is poly synthesized .
Yet, Merck is touting its Grastek at achieving annual sales of $1 billion....,and such mono therapies are very expensive with significant probabilities of major side effects.
WF10 is a disruptive treatment therapy in that it is the only known...at least to me..that can effectively treat poly synthesized patients suffering from the various allergic diseases.
And, patient response is of a substantial magnitude and much much higher than either Grastek or Circassia's suite of mono products ... Do some DD here
With most of the allergic population poly synthesized and being substantively effective as treatment therapy, WF10 is a game changer in this most frequent doctor visit health issue .
If Merck can claim $1 billion in peak sales, then reaching such levels will be a piece of cake for WF10
Valuation:
Based on the totality of information available re Phase 11 results for WF10, it is virtually certain that those results will faithfully replicate highly confident and predictable results from the initial study in 2010.
That being so, we can now concentrate on impacts of such results on share price.
WF10 will be used to treat Allergic Rhinitus ( AR ). In the US, as elsewhere, AR affects about 20 % of the population. It is the single most important contributor to hospital/doctor visits in the US accounting for about 3 % of all visits.
It is a chronic condition, with sufferers taking a wide variety of symptom relieveing medication over the long term.A longer effect can be achieved by immunotherapy. However, uptake is low due to long and complex dosing schedules ( 80-100 injections or daily pill over 3-5 years.
This market in the US is currently estimated to be approaching $15 billion.
Both Circassia and Nuvo intend to address this substantial and poorly addressed market with novel immunotherapy technology using short patient friendly dosing schedules ( 4 injections over 3 months for Circassia Spire and 5 dosings over 5 days by WF10 ).
An important distinction between Circassia's 4 Spire drugs ( one each for cat allergy, HDM, grass and ragweed ) and WF10 is that the Spire drugs are allergen specific, requiring expensive discrinmant testing prior to treatment.
This is not required of WF10 as it has been shown to treat all allergies ie one treatment suits all allergies.
Circassia has estimated the combined US and EU peak sales of its 4 drugs combined at about $3.2 billion US or about $1.6 billion for the US market alone.
Nuvo has estimated this market at up to $1.1 billion US.
Nuvo' s study concentrated only on allergists.
However, as WF10 requires no allergen tests, family physicians will be able to prescribe and perform infusion therapy directly..
In other words, Nuvo' s study probably underestimated peak sales.
Now, with those facts and descriptors out of the way we can examine probable valuation of WF10 at Feb/15.
As Cannacord has done so for Circassia, we can use its conventional risked and discounted medical models, as proxies for WF10.
Cannacords parameters are........p ( probability of success ) of 42 % in Phase 2, 60 % after completing phase 2, and 80 % for phase 3//// WACC of 15 %, discount rate of 10 %.
Cat spire is in phase 3 and HDM, Grass and Ragweed are in phase 2.
The discounted, risk adjusted valuations emerging from the model were.....
......... Cat = 134 m pence ( $215 m US )
........HDM = 58 m pence ( $93 million US )
........Rag =57 m pence ( $90 million US )
........Grass = 38 m pence ( $61 million US
Total combined risk adjusted sum of parts adds to $459 million US.
As WF10 treats all four of these allergies and in a more efficient manner, this should be a good and reliable estimate of the risk adjusted current value ( NPV ) of WF10 as at mid -February, when the results of phase 2 are released.
That value should increase through out 2015, as different dosing schedules trials advance specific efficacy issues (eh higher or lower dose, 3 dosing days rathern than 5 days etc.
Note also that WF10 is patented for other allergic diseases such as asthma and conjunctivis, each having markets comparable to AR. Circassia does not have this.
As physicians consider only safety in cross prescriptions, They will be able to prescribe WF10 for those health issues as well.
Taken together, success in the recent Phase 11 trials should boost Nuvo' s market cap to levels above $500 million U.S.
This will not happen in one fell swoop, but a doubling of share price from current levels upon the success of such results would not be unexpected
Source: Sotckhouse.com
Nuvo's WF10 and WF10 Valuation Using Cannacord Circassian discount model
TSX: NRI OTC: NRIFF
Most investors here have not yet understood the real significance of WF10 in the treatment of AR and other allergic illnesses.
No drug has yet been developed that can effectively treat poly synthesized patients for AR or the other immune diseases such as conjunctivitis and allergic asthma.
Each and every drug either developed ( like Mercks Grastek ) or in clinical trials (eg Circasia ) is based on only mono synthesized patients .
These must go thru initial allergic testing to identify the precipitate agent ... Ragweed , dust mites etc.
Yet , after administering their specific drug, levels of patient response while statistically significant is rather modest .
The reason for such a tepid patient response is that most of the allergic population is poly synthesized .
Yet, Merck is touting its Grastek at achieving annual sales of $1 billion....,and such mono therapies are very expensive with significant probabilities of major side effects.
WF10 is a disruptive treatment therapy in that it is the only known...at least to me..that can effectively treat poly synthesized patients suffering from the various allergic diseases.
And, patient response is of a substantial magnitude and much much higher than either Grastek or Circassia's suite of mono products ... Do some DD here
With most of the allergic population poly synthesized and being substantively effective as treatment therapy, WF10 is a game changer in this most frequent doctor visit health issue .
If Merck can claim $1 billion in peak sales, then reaching such levels will be a piece of cake for WF10
Valuation:
Based on the totality of information available re Phase 11 results for WF10, it is virtually certain that those results will faithfully replicate highly confident and predictable results from the initial study in 2010.
That being so, we can now concentrate on impacts of such results on share price.
WF10 will be used to treat Allergic Rhinitus ( AR ). In the US, as elsewhere, AR affects about 20 % of the population. It is the single most important contributor to hospital/doctor visits in the US accounting for about 3 % of all visits.
It is a chronic condition, with sufferers taking a wide variety of symptom relieveing medication over the long term.A longer effect can be achieved by immunotherapy. However, uptake is low due to long and complex dosing schedules ( 80-100 injections or daily pill over 3-5 years.
This market in the US is currently estimated to be approaching $15 billion.
Both Circassia and Nuvo intend to address this substantial and poorly addressed market with novel immunotherapy technology using short patient friendly dosing schedules ( 4 injections over 3 months for Circassia Spire and 5 dosings over 5 days by WF10 ).
An important distinction between Circassia's 4 Spire drugs ( one each for cat allergy, HDM, grass and ragweed ) and WF10 is that the Spire drugs are allergen specific, requiring expensive discrinmant testing prior to treatment.
This is not required of WF10 as it has been shown to treat all allergies ie one treatment suits all allergies.
Circassia has estimated the combined US and EU peak sales of its 4 drugs combined at about $3.2 billion US or about $1.6 billion for the US market alone.
Nuvo has estimated this market at up to $1.1 billion US.
Nuvo' s study concentrated only on allergists.
However, as WF10 requires no allergen tests, family physicians will be able to prescribe and perform infusion therapy directly..
In other words, Nuvo' s study probably underestimated peak sales.
Now, with those facts and descriptors out of the way we can examine probable valuation of WF10 at Feb/15.
As Cannacord has done so for Circassia, we can use its conventional risked and discounted medical models, as proxies for WF10.
Cannacords parameters are........p ( probability of success ) of 42 % in Phase 2, 60 % after completing phase 2, and 80 % for phase 3//// WACC of 15 %, discount rate of 10 %.
Cat spire is in phase 3 and HDM, Grass and Ragweed are in phase 2.
The discounted, risk adjusted valuations emerging from the model were.....
......... Cat = 134 m pence ( $215 m US )
........HDM = 58 m pence ( $93 million US )
........Rag =57 m pence ( $90 million US )
........Grass = 38 m pence ( $61 million US
Total combined risk adjusted sum of parts adds to $459 million US.
As WF10 treats all four of these allergies and in a more efficient manner, this should be a good and reliable estimate of the risk adjusted current value ( NPV ) of WF10 as at mid -February, when the results of phase 2 are released.
That value should increase through out 2015, as different dosing schedules trials advance specific efficacy issues (eh higher or lower dose, 3 dosing days rathern than 5 days etc.
Note also that WF10 is patented for other allergic diseases such as asthma and conjunctivis, each having markets comparable to AR. Circassia does not have this.
As physicians consider only safety in cross prescriptions, They will be able to prescribe WF10 for those health issues as well.
Taken together, success in the recent Phase 11 trials should boost Nuvo' s market cap to levels above $500 million U.S.
This will not happen in one fell swoop, but a doubling of share price from current levels upon the success of such results would not be unexpected
Source: Sotckhouse.com
Meet this gem and go for long
Aldeyra Therapeutics Inc
Ticker: ALDX
Current Price: $9.85
Outstanding Shares: 5.57 millions only
Market Cap: $49.56 Millions
Institution own 81 percent
Product: Working on rare disease(s)
in $9.15 today and digging more
$ALDX will participate in the Canaccord Genuity Rare Disease, BioPharma One-on-One Day, being held on Tuesday, February 3, 2015
Data might come in Q2 2015
DVAX to release update on hepatitis B vaccine in February, 2015
DVAX to release update on hepatitis B vaccine in February, 2015
Nuvo’s stock would be quoted at $100
"At that valuation, Nuvo’s stock (TSX: NRI OTC: NRIFF) would be quoted at $100. This isn’t a prediction, of course. But I think it does lay out rather neatly that Nuvo Research is not a typical biotech speculation".
http://www.theglobeandmail.com/globe-investor/investment-ideas/nuvo-research-is-not-your-typical-biotechnology-stock/article21563028/
Nuvo’s stock would be quoted at $100
"At that valuation, Nuvo’s stock would be quoted at $100. This isn’t a prediction, of course. But I think it does lay out rather neatly that Nuvo Research is not a typical biotech speculation".
http://www.theglobeandmail.com/globe-investor/investment-ideas/nuvo-research-is-not-your-typical-biotechnology-stock/article21563028/
Nuvo Research Inc (TSX: NRI, OTC: NRIFF) will release WF10 phase 2a result in mid February 2015. WF10 is said to be blockbuster and game changer drug.
Nuvo Already has 2/3 FDA approved Drugs
Only 10.7 million shares outstanding
Cash in hand: 60 million
Current market cap: 88 million
Soon be listing on the Nasdaq
Considerable interest in a buy-out/take-over possibility
Valuation of WF10 - If WF10 is successful in these trials and is then approved, there is no reason Nuvo could not go to $500,000,000 to $1,000,000,000 market cap
Keep your eye's on this one! It's about to get very interesting, very soon!
Do your own DD and dig more
Nuvo Research Inc (TSX: NRI, OTC: NRIFF) will release WF10 phase 2a result in mid February 2015. WF10 is said to be blockbuster and game changer drug.
Nuvo Already has 2/3 FDA approved Drugs
Only 10.7 million shares outstanding
Cash in hand: 60 million
Current market cap: 88 million
Soon be listing on the Nasdaq
Considerable interest in a buy-out/take-over possibility
Valuation of WF10 - If WF10 is successful in these trials and is then approved, there is no reason Nuvo could not go to $500,000,000 to $1,000,000,000 market cap
Keep your eye's on this one! It's about to get very interesting, very soon!
Do your own DD and dig more
"The stock market is a giant distraction to the business of investing."
- John Bogle
The result indicates, people dumping junk food from their diet. I won't surprise if they start closing of stores in the near future
TSX: NRI is going to break 52 weeks high today
http://web.tmxmoney.com/quote.php?qm_symbol=nri
Nuvo Research Inc. (TSX:NRI OTC NRIFF) CEO John London Podcast Interview
http://www.midasletter.com/2014/12/uvo-research-inc-tsxnri-ceo-john-london-podcast-interview/
Phase 2A result by Q1 2015
Great upside potential
Interview with the CEO: Dynavax Technologies Corporation (DVAX)
http://www.twst.com/interview/30547#sthash.JEhrCSDm.dpuf
pre market on fire ...
Royal Bank to buy U.S.-based City National in $5.4B US deal http://www.cbc.ca/news/business/royal-bank-to-buy-u-s-based-city-national-in-5-4b-us-deal-1.2927505
Nuvo Research Inc. (TSX:NRI) CEO John London Podcast Interview
http://www.midasletter.com/2014/12/uvo-research-inc-tsxnri-ceo-john-london-podcast-interview/
Dynavax Technologies Corporation Shares Witness Large Outflow of Money
http://candlestrips.com/dynavax-technologies-corporation-shares-witness-large-outflow-of-money/38823/